Compare Adaptive Biotechnologies Corp (ADPT) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Harmony Gold Mining Co. — how do they compare? Adaptive Biotechnologies Corp trades at $25.31 (market cap $4.04B), while Harmony Gold Mining Co. trades at $19.93 (market cap $12.24B). The key difference: Harmony Gold Mining Co. is far larger — about 3× Adaptive Biotechnologies Corp's market cap, and Harmony Gold Mining Co. pays a 2.09% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HMY | |
|---|---|---|
Market Cap | $4.04B | $12.24B |
Sector | Health | Basic Materials |
52-Week High | $25.45 | $26.04 |
52-Week Low | $12.30 | $12.61 |
Enterprise Value | $4.10B | $12.58B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Harmony Gold Mining (HMY) trades at $19.88, down 0.1% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, supported by a strategic pivot to gold-copper production. Recent news highlights operational progress, including copper profit growth and diversification efforts.
HMY offers value with a P/E of 12.26 and robust profitability margins, but faces risks from gold price volatility and mixed analyst sentiment. The stock's outlook is supported by earnings growth and diversification, though investor caution is warranted due to Fed policy sensitivity and execution risks in expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
